磷脂酰肌醇蛋白聚糖-3 靶向治疗肝细胞癌：生物学见解与治疗策略

Glypican-3-targeted therapy in hepatocellular carcinoma: biological insights and therapeutic strategies.

靶向 GPC3 的药物在癌症治疗中的研究进展

Research progress of drugs targeting GPC3 in cancer therapy.

靶向 glypican-3 作为肝癌治疗的新前沿

Targeting glypican-3 as a new frontier in liver cancer therapy.

经 mRNA-LNP 平台靶向递送 IFN-α-抗 GPC3 融合蛋白在肝细胞癌中激发强效抗肿瘤免疫

Targeted delivery of IFN-α-anti-GPC3 fusion protein via mRNA-LNP platform elicits potent anti-tumor immunity in hepatocellular carcinoma.

双靶向 CAR-T 疗法推进肝癌治疗

Advancing liver cancer treatment with dual-targeting CAR-T therapy.

靶向 NK 细胞 CD16A 与肝细胞癌 GPC3：一种治疗性双特异性抗体的开发与功能验证

Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody.

本研究引入了三项创新：(1) 一种克服多态性限制的物种特异性 CD16A 结合剂，(2) Fc 结构域工程化改造 (N297A) 以优化稳定性和安全性，以及 (3) 与索拉非尼的协同联合策略。这些结果为 GPC3+ 实体瘤免疫治疗提供了一个可转化的框架。

OHSV2-DSTE(FAP5/CD3)、CAR-T 细胞与免疫毒素高阶联合在肝细胞癌中协同抗肿瘤效应的概念性探索

A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTE(FAP5/CD3), CAR-T cells, and immunotoxins in hep

这种高阶联合代表了一种针对肝细胞癌的新型多波次免疫治疗策略。

GPC-3 在肝细胞癌中：一种新型生物标志物和分子靶点

GPC-3 in hepatocellular carcinoma; A novel biomarker and molecular target.

整合成像探针与双特异性抗体开发实现体内靶向表达 Glypican-3 的肝细胞癌

Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma.

靶向 FAP 和 GPC3 的双特异性 CAR-T 细胞具有治疗肝细胞癌的潜力

Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma.